LEO Pharma Acquires Replay for Rare Genetic Skin Treatment

LEO Pharma, a Danish drugmaker, announced an agreement to buy U.S. drug developer Replay for $50 million upfront. This move enhances LEO Pharma's dermatology business by adding a novel treatment platform aimed at resolving rare genetic skin diseases, though milestone payment details remain undisclosed.

In a significant move, Danish pharmaceutical company LEO Pharma has agreed to purchase U.S.-based drug developer Replay. The transaction, valued at $50 million upfront, aims to integrate Replay's experimental treatment capabilities for rare genetic skin conditions into LEO Pharma's dermatology business.

The acquisition deal includes milestone payments and tiered royalties. However, specific details regarding the milestones have not been made public.

This strategic acquisition is expected to bolster LEO Pharma's dermatology offerings by providing innovative solutions to uncommon genetic skin disorders, further diversifying its product range in this niche sector.